ClinicalTrials.gg
CompletedNCT03028285Updated Jul 14, 2020

Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers

A Phase 1 interventional study of arginine sodium succinate in Peripheral Vascular Disease, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Completed at 2 sites in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-14.

Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2016, registered Jan 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Unifusol (R) is a solution of arginine sodium succinate for intravenous infusions. Its effects include vasodilation, protection of inner layer of blood vessels and improvement of blood viscosity. The present phase I study is aimed to evaluate the safety and tolerability of Unifusol infusions in healthy volunteers.

Read the detailed description

Unifuzol, solution for infusions,("NTFF POLYSAN" Ltd., Russia) contains succinic acid and arginine as active ingredients; it has demonstrated cardioprotective, anti-ischemic, endothelial protective and fibrinolytic activity in pre-clinical studies and is considered for clinical trials in peripheral vascular disease.

The primary aim of the present Phase I study is to assess safety and tolerability of Unifusol (1.4% solution for infusions) at different infusion rates in healthy volunteers.

Study objectives:

  1. Assess the safety parameters (vital signs, the incidence of AEs, SAEs, laboratory abnormalities) during infusion of Unifusol (1.4% solution for infusions) in healthy volunteers at different infusion rates.

    • administration of a single infusion of 250 ml at a rate of 3 ml / min.
    • administration of a single infusion of 250 ml at a rate of 4.5 ml / min
    • administration of a single infusion of 500 ml at a rate of 4.5 ml / min
  2. Study the pharmacokinetics parameters of the active components of the Unifusol (succinic acid and arginine) in healthy volunteers after single infusion at a dose of 250 ml at a rate of 4.5 ml / min.

Study methods:

  1. Determination of pharmacokinetic parameters of succinic acid administered at a single Unifusol infusion dose 250 ml at a rate of 4.5 ml / min (AUC, Cmax, Tmax, T1 / 2);
  2. Determination of pharmacokinetic parameters of arginine after a single Unifusol infusion at a dose 250 ml at a rate of 4.5 ml / min (AUC, Cmax, Tmax, T1 / 2);
  3. Determination of individual variations of the pharmacokinetic parameters of succinic acid and arginine in healthy volunteers;
  4. Identification of significant gender differences in the pharmacokinetics of the active ingredients of Unifusol (succinic acid and arginine) in healthy volunteers;
  5. Determination of the number of compartments in the pharmacokinetic model which will be most appropriate to the measured concentrations after a single infusion (single-chamber, two-chamber or three-chamber pharmacokinetic model).
02

Conditions studied

  • Peripheral Vascular Disease

Keywords

  • succinate
  • arginine
  • vasodilation
  • peripheral vascular disease
03

In context

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

This study's enrollment of 48 is below the median of 80 across 327 interventional studies indexed under Peripheral Vascular Diseases.

Browse Peripheral Vascular Diseases studies →

Lead sponsor

POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 23 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy condition, as verified by standard clinical, laboratory and instrumental methods of examination.
  2. The (BMI) of 18.5 to 30 and a body weight above 50 kg.
  3. Signed .
  4. For men - consent to use the double-barrier method during the course of the study, and for 90 days after the study completion.
  5. For women - negative pregnancy test, absence of lactation, and consent to use the double-barrier method of contraception during the study and for 90 days after study completion. In the case of hormonal contraceptive use, the intake must be canceled no later than 2 months before the start of the study.

Exclusion criteria

Exclusion Criteria:

  1. Intolerance or to the components of the study drug.
  2. Chronic diseases of the cardiovascular, bronchopulmonary (including bronchospastic disease), neuroendocrine system, chronic diseases of the gastrointestinal tract, liver, kidneys, blood, immune system, mental illness or substance abuse, or a history of alcoholism.
  3. Acute infectious diseases within 4 weeks before the start of the study.
  4. Any abnormalities of the laboratory findings before inclusion.
  5. The presence of mental disorders, or the history of mental illness.\
  6. Intake of medications and/or nutritional supplements for 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug, or using drugs that have a significant effect on hemodynamics, liver function, etc. (for instance, barbiturates, omeprazole, cimetidine) for 2 months prior to the first dose of study medication. Receiving herbal medicines and herbal supplements during the 28 days before the first dose of study medication.
  7. Hormonal methods of with systemic effects (including oral and transdermal contraceptives, injectable progesterone, subcutaneous implants with a progestin intrauterine device with progesterone release) and hormone replacement therapy within 60 days prior to the first dose of study medication.
  8. The injection of any drug, depot (slow release) or the use of drug implant within 3 months prior to the administration of the study drug.
  9. Abnormalities of vital signs: systolic blood pressure below 100 mm Hg or higher than 130 mm Hg; diastolic blood pressure below 60 mmHg or above 90 mm Hg; heart rate below 60 beats / min or above 90 beats / min.
  10. Data of 12-lead demonstrating the > 450 msec or the QRS> 120 ms on screening visit.
  11. Blood donation (450 ml of blood or more) in less than 3 months prior to inclusion.
  12. Participation in clinical trials of drugs in 3 months before inclusion.
  13. The regular consumption of more than 5 units of alcohol per week (each unit is equal to 30 ml of ethanol or 325 ml of beer) or the history of alcoholism, drug addiction, drug abuse.
  14. A positive test for alcohol in the exhaled air.
  15. Smoking more than 10 cigarettes per day.
  16. A positive urine test for drugs, such as amphetamine, marijuana, morphine, cocaine and methamphetamine, and tricyclic antidepressants, as revealed in urine by immunoassay analysis.
  17. The positive results of the analyzes for or C, , and/or syphilis.
  18. Unwilling or unable to give up alcohol intake, smoking and excessive exercise 48 hours prior to study drug administration and up to 96 hours after administration of the drug, as well as food and beverages containing methylxanthines and grapefruit / grapefruit juice from the day prior to the screening visit and at follow-up.
  19. Compliance to a special diet (eg. vegetarian) or lifestyle (including night work and extreme exercise, such as sports or weight lifting) that may interfere with the study procedures.
  20. Planning inpatient treatment of the volunteer within one month after the first injection of the study drug.
  21. Lack of intention to comply with the study regimen.
  22. Obvious or probable inability of volunteer, according to the judgement of the researcher, to understand and evaluate information about the study and consciously sign the form, in particular with respect to the expected risks and possible discomfort.
  23. Expected problem with the placement of venous catheters or performing vein puncture.
  24. Pregnancy or breast-feeding; unwillingness or inability of a woman of childbearing age to use acceptable methods of barrier contraception, according to the protocol, starting at least 14 days prior to the first dose of study medication and for 90 days after study completion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Unifusol 250 ml IV, 3 ml/mil

    Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.

    Drug: arginine sodium succinate

  • Experimental
    Unifusol 250 ml IV, 4.5 ml/min

    Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min

    Drug: arginine sodium succinate

  • Experimental
    Unifusol 500 ml IV, 4.5 ml/min

    Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min

    Drug: arginine sodium succinate

Interventions

  • Drugarginine sodium succinate

    Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.

    Also known as: Unifusol

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events, derangements of vital signs, and laboratory abnormalities

    Absence of vital disorders, SAEs, laboratory abnormalities, and the incidence of AEs

    Time frame: 18-26 days

Secondary outcomes

  1. Area under the plasma concentration of arginine versus time curve

    AUC

    Time frame: 6 hours

  2. Area under the plasma concentration of succinic acid versus time curve

    AUC

    Time frame: 6 hours

  3. Peak Plasma Concentration of arginine

    Cmax

    Time frame: 6 hours

  4. Peak Plasma Concentration of succinic acid

    Cmax

    Time frame: 6 hours

  5. Time to peak Plasma Concentration of arginine

    Tmax

    Time frame: 6 hours

  6. Time to peak Plasma Concentration of succinic acid

    Tmax

    Time frame: 6 hours

07

Study locations

2 sites
  • Clinical diagnostic laboratory of City Clinical Hospital named after I.V.Davydovsky
    Moscow, 109240, Russian Federation
  • Research Center for Eco-safety, Ltd.
    Saint Petersburg, 196143, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Jan 2017, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2017
First posted
Jan 23, 2017
StartActual
Jul 15, 2016
Primary completionActual
Jan 19, 2017
CompletionActual
Jan 26, 2017
Last update
Jul 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03028285
Responsible party
Sponsor
First posted
Jan 23, 2017
Start date
Jul 15, 2016
Primary completion
Jan 19, 2017
Completion
Jan 26, 2017
Last update
Jul 14, 2020

Study contacts

Vasily B Vasilyuk, MD, PhD
principal investigator · Research Center for Eco-safety

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion